ProQR Therapeutics

ProQR Therapeutics Liabilities

The The Liabilities of ProQR Therapeutics (PRQR) as of Nov 16, 2026 is 74.44 M EUR. In the previous year, The Liabilities was 82.22 M EUR — a change of -9.46% (lower).

Liabilities

74.44 MEUR

YoY

-9.46%

Last updated:

In 2025, ProQR Therapeutics's total liabilities amounted to 74.44 M EUR, a -9.46% difference from the 82.22 M EUR total liabilities in the previous year.

The ProQR Therapeutics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
17.55 M EUR
Jan 1, 2019
26.61 M EUR
Jan 1, 2020
51.61 M EUR
Jan 1, 2021
109.57 M EUR
Jan 1, 2022
111.68 M EUR
Jan 1, 2023
106.59 M EUR
Jan 1, 2024
82.22 M EUR
Jan 1, 2025
74.44 M EUR
The ProQR Therapeutics Liabilities history
YEARLiabilitiesYoY
74.44 MEUR-9.46%
82.22 MEUR-22.87%
106.59 MEUR-4.55%
111.68 MEUR+1.92%
109.57 MEUR+112.29%
51.61 MEUR+93.99%
26.61 MEUR+51.63%
17.55 MEUR+6.05%
16.54 MEUR+26.43%
13.09 MEUR+16.84%
11.20 MEUR+58.41%
7.07 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProQR Therapeutics Stock analysis

What does ProQR Therapeutics do? ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing ProQR Therapeutics's Liabilities

ProQR Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ProQR Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ProQR Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ProQR Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ProQR Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ProQR Therapeutics stock

The Liabilities of ProQR Therapeutics is 74.44 M EUR in 2025.

The Liabilities of ProQR Therapeutics changed from 82.22 M EUR to 74.44 M EUR, representing a -9.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities ProQR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's ProQR Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProQR Therapeutics

All Key Metrics — ProQR Therapeutics